TY  - GEN
AU  - Kumar,S K
AU  - Ma,E
AU  - Engebretson,A E
AU  - Buadi,F K
AU  - Lacy,M Q
AU  - Dispenzieri,A
AU  - Duh,M S
AU  - Lafeuille,M-H
AU  - Lefebvre,P
AU  - Cheng,W Y
AU  - Dea,K
AU  - Rembert,D
AU  - Patt,D
AU  - Niculescu,L
AU  - Quick,M
AU  - Rajkumar,S V
TI  - Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma
SN  - 1476-5551
PY  - 2016///0915
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - economics
KW  - Bortezomib
KW  - administration & dosage
KW  - Cyclophosphamide
KW  - Dexamethasone
KW  - Follow-Up Studies
KW  - Health Care Costs
KW  - statistics & numerical data
KW  - Health Resources
KW  - Humans
KW  - Lenalidomide
KW  - Multiple Myeloma
KW  - diagnosis
KW  - Neoplasm Staging
KW  - Prognosis
KW  - Survival Rate
KW  - Thalidomide
N1  - Publication Type: Letter; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1038/leu.2015.225
ER  -